BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10708289)

  • 1. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.
    Nieuwkerk PT; Gisolf EH; Colebunders R; Wu AW; Danner SA; Sprangers MA
    AIDS; 2000 Jan; 14(2):181-7. PubMed ID: 10708289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
    Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
    AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.
    Gatanaga H; Aizawa S; Kikuchi Y; Tachikawa N; Genka I; Yoshizawa S; Yamamoto Y; Yasuoka A; Oka S
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1493-8. PubMed ID: 10580399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
    Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.
    Patricia E; Domingo P; Gutierrez M; Gracia M; Fuster M; Molto J; Puig J; Perez-Alvarez N; Clotet B; Negredo E
    Curr HIV Res; 2010 Sep; 8(6):467-70. PubMed ID: 20636275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
    Teira R; Cámara MM; Escobar A; Muñoz P; López de Munain J; Santamaría JM
    Med Clin (Barc); 2003 Oct; 121(14):532-4. PubMed ID: 14599408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
    Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
    J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
    Tsuchiya K; Hirabayashi Y; Imai K; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Yasuoka A; Oka S; Kimura S
    Kansenshogaku Zasshi; 2003 Jun; 77(6):436-42. PubMed ID: 12872693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.